Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.

NCT02331641

Colorectal Liver Metastases Colon Cancer

COMPLETED

Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases

NCT01683357

Liver Metastases

COMPLETED

Chemotherapy for Resectable Colorectal Liver Metastases

NCT04513457

Metastatic Colorectal Cancer Metastatic Liver Cancer

COMPLETED

Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.

NCT05273489

Colorectal Cancer Metastatic Liver Metastases

COMPLETED

Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma

NCT03999593

Cholangiocarcinoma Surgery--Complications

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients affected by CLMs and trated with neoadjuvant systemic chemotherapy and then hepatectomy were reviewed with the intent to assess the occurrence of liver atrophy, which is a sign of liver dysfunction and a source of morbidity expecially in patients treated with major or extended hepatectomy. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. Then, we planned to review our cases with the above mentioned endpoint.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Stage IV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No post-chemotherapy liver atrophy

Patients treated with systemic chemotherapy, then hepatectomy for colorectal liver metastases. No occurrence of post-chemotherapy liver atrophy as measured by computed-tomography liver volumetry.

Hepatectomy

Intervention Type PROCEDURE

Surgical removal of a part of the liver

Yes post-chemotherapy liver atrophy

Patients treated with systemic chemotherapy, then hepatectomy for colorectal liver metastases. Yes, occurrence of post-chemotherapy liver atrophy as measured by computed-tomography liver volumetry.

Hepatectomy

Intervention Type PROCEDURE

Surgical removal of a part of the liver

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hepatectomy

Surgical removal of a part of the liver

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Liver resection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consecutive patients with multiple CLMs treated with preoperative chemotherapy and parenchymal sparing surgery;
* Only patients with available volumetry of the pre- and post-chemotherapy abdominal enhanced computed tomography (CT) images;

Exclusion Criteria

* Patients who underwent preoperative PVE;
* Patients treated by major hepatectomies; Patients treated with thermal ablation alone or in association with hepatic resection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No